Product Identification

Product Name

(5alpha)-3,14-Dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one

Synonyms

17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one
1-n-Allyl-14-Hydroxynordihydromorphinone
1-n-Allyl-7,8-dihydro-14-hydroxynormorphinone
n-Allyl-Noroxymorphone

CAS

465-65-6

Formula

C19H21NO4

Molecular Weight

327.38

EINECS

207-365-7

RTECS

QD2260000

RTECS Class

Drug; Mutagen; Reproductive Effector

Merck

12,6449

Beilstein/Gmelin

1089071

Physical and Chemical Properties

Appearance

Crystals from ethyl acetate.

Solubility in water

Insoluble

Melting Point

184

pKa/pKb

7.39 (pKb)

Usage

Medication.

First Aid Measures

Ingestion

Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended.

Inhalation

If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention.

Skin

Naloxone has a poor bioavailability when given orally, thus systemic adverse effects would be limited and gastrointestinal decontamination is rarely needed. See recommendations in the parenteral exposure section for treatment information.

Eyes

If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention.

Handling and Storage

Storage

Protect from excessive light.Should be protected from excessive moisture and exposure to air.Should be stored below 30C.

Handling

All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.

Hazards Identification

Inhalation

Increased respiratory rate may be seen with large doses. Pulmonary edema has been noted in a few cases of therapeutic use.

Exposure Controls/Personal Protection

Personal Protection

Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.

Respirators

Use NIOSH/MSHA approved respirator appropriate for exposure of concern.

Exposure Effects

With therapeutic use - seizures have been rarely seen with therapeutic use. Memory impairment has been reported in high dose therapy. Pregnancy Category B <br>No data were available to assess the teratogenic potential of this agent. <br>Naloxone is not known to produce adverse neonatal effects other than the possible precipitation of withdrawal symptoms in narcotic addicted mothers and their infants. Naloxone is clearly the drug of choice over nalorphine to reverse respiratory depression in the neonate.

Fire Fighting Measures

Fire Fighting

Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.

Accidental Release Measures

Small spills/leaks

Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.

Stability and Reactivity

Stability

Not particularly hygroscopic; can oxidize; relatively stable in heat hydrochloride.

Incompatibilities

Strong oxidizing agents.